Letter to the Editor Regarding The Use of Vancomycin Powder in Modern Spine Surgery: Systematic Review and Meta-Analysis of the Clinical Evidence

2016 ◽  
Vol 88 ◽  
pp. 675 ◽  
Author(s):  
Nathan Evaniew ◽  
Emilie P. Belley-Côté ◽  
Moin Khan ◽  
Michelle Ghert
Keyword(s):  
Systematic Review ◽  
Spine Surgery ◽  
Clinical Evidence ◽  
Meta Analysis ◽  
Letter To The Editor ◽  
Vancomycin Powder

The Use of Vancomycin Powder In Modern Spine Surgery: Systematic Review and Meta-Analysis of the Clinical Evidence

2015 ◽  
Vol 83 (5) ◽  
pp. 816-823 ◽  
Author(s):  
Joshua Bakhsheshian ◽  
Nader S. Dahdaleh ◽  
Sandi K. Lam ◽  
Jason W. Savage ◽  
Zachary A. Smith
Keyword(s):  
Systematic Review ◽  
Spine Surgery ◽  
Clinical Evidence ◽  
Meta Analysis ◽  
Vancomycin Powder

Application of vancomycin powder into the wound during spine surgery: Systematic review and meta-analysis

2014 ◽  
Vol 58 (3) ◽  
pp. 182-191 ◽  
Author(s):  
G. Alcalá-Cerra ◽  
A.J. Paternina-Caicedo ◽  
L.R. Moscote-Salazar ◽  
J.J. Gutiérrez-Paternina ◽  
L.M. Niño-Hernández
Keyword(s):  
Systematic Review ◽  
Spine Surgery ◽  
Meta Analysis ◽  
Vancomycin Powder

scholarly journals Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 351
Author(s):  
Massimiliano Creta ◽  
Giuseppe Celentano ◽  
Luigi Napolitano ◽  
Roberto La Rocca ◽  
Marco Capece ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bladder Cancer ◽  
Relative Risk ◽  
Clinical Studies ◽  
Clinical Evidence ◽  
Meta Analysis ◽  
Bladder Tumour ◽  
Signalling Pathways ◽  
Reductase Inhibitors ◽  
The Impact

Bladder cancer (BCa) is an endocrine-related tumour and the activation of androgen signalling pathways may promote bladder tumorigenesis. We summarized the available preclinical and clinical evidence on the implications of the manipulation of androgen signalling pathways on the outcomes of BCa therapies. A systematic review was performed in December 2020. We included papers that met the following criteria: original preclinical and clinical research; evaluating the impact of androgen signalling modulation on the outcomes of BCa therapies. Six preclinical and eight clinical studies were identified. The preclinical evidence demonstrates that the modulation of androgen receptor-related pathways has the potential to interfere with the activity of the Bacillus Calmette Guerin, doxorubicin, cisplatin, gemcitabine, and radiotherapy. The relative risk of BCa recurrence after transurethral resection of the bladder tumour (TURBT) is significantly lower in patients undergoing therapy with 5 alpha reductase inhibitors (5-ARIs) or androgen deprivation therapy (ADT) (Relative risk: 0.50, 95% CI: 0.30–0.82; p = 0.006). Subgroup analysis in patients receiving 5-ARIs revealed a relative risk of BCa recurrence of 0.46 (95% CI: 0.22–0.95; p = 0.040). A significant negative association between the ratio of T1 BCa patients in treated/control groups and the relative risk of BCa recurrence was observed. Therapy with 5-ARIs may represent a potential strategy aimed at reducing BCa recurrence rate, mainly in patients with low stage disease. Further studies are needed to confirm these preliminary data.

Sign in / Sign up

Export Citation Format

Share Document